Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Common Equity (2018 - 2025)

X4 Pharmaceuticals' Common Equity history spans 8 years, with the latest figure at $186.3 million for Q4 2025.

  • For Q4 2025, Common Equity rose 741.08% year-over-year to $186.3 million; the TTM value through Dec 2025 reached $186.3 million, up 741.08%, while the annual FY2025 figure was $186.3 million, 741.08% up from the prior year.
  • Common Equity reached $186.3 million in Q4 2025 per XFOR's latest filing, up from $61.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $186.3 million in Q4 2025 to a low of $1.0 million in Q1 2024.
  • Average Common Equity over 5 years is $61.6 million, with a median of $61.7 million recorded in 2022.
  • Peak YoY movement for Common Equity: plummeted 98.0% in 2024, then skyrocketed 2114.67% in 2025.
  • A 5-year view of Common Equity shows it stood at $64.4 million in 2021, then increased by 14.96% to $74.1 million in 2022, then crashed by 30.99% to $51.1 million in 2023, then crashed by 56.65% to $22.1 million in 2024, then soared by 741.08% to $186.3 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Common Equity are $186.3 million (Q4 2025), $61.6 million (Q3 2025), and $4.0 million (Q2 2025).